AI驱动的在线自适应放疗在前列腺癌中的活动时间与剂量学获益
该研究分析了31例接受AI集成直线加速器在线自适应放疗(oART)的前列腺癌患者,比较预测计划与自适应计划的每日剂量体积直方图指标。结果显示oART显著改善靶区覆盖,淋巴结阴性组PTV V95%提高10.4%、阳性组提高11.8%,而危及器官剂量学指标无显著差异(p>0.1)。前列腺-only和淋巴结病例的中位治疗时间分别为25分钟和32分钟。
要点
- 危及器官剂量学指标在预测计划与自适应计划间无显著差异(p>0.1)。
- 前列腺-only病例中位治疗时间25分钟,淋巴结病例32分钟。
核心结论
- AI驱动的在线自适应放疗在前列腺癌中显著改善靶区覆盖,且未显著增加危及器官剂量。
研究设计与样本
- 单中心分析31例接受AI集成直线加速器oART的前列腺癌患者,按淋巴结是否受累分组。
- 每日采集CBCT,AI自动分割危及器官(直肠、膀胱、肠道),靶区手动勾画。
- 每例生成预测计划(原计划通量映射至当日解剖)和自适应计划(完全通量再优化),比较每日DVH指标。
主要发现
- PTV V95%在淋巴结阳性组提高10.4%,淋巴结阴性组提高11.8%。
- CTV D98%在淋巴结阳性组提高2.6%,淋巴结阴性组提高2.9%。
- 淋巴结病例中PTV2 V95%提高3.1%,CTV2 D98%提高2.2%。
- 危及器官DVH指标(膀胱V65Gy、肠道V45Gy、直肠V50Gy)差异无统计学意义(p>0.1)。
- 前列腺-only病例中位治疗时间25分钟,淋巴结病例32分钟。
关键数值与推荐
- 前列腺-only病例CTV1包括前列腺和精囊,PTV1外放5 mm(后方8 mm)。
- 淋巴结病例CTV2包括盆腔淋巴结,PTV2各向同性外放5 mm。
- 比较的DVH指标包括PTV V95%、CTV D98%、膀胱V65Gy、肠道V45Gy、直肠V50Gy。
临床怎么用
- AI驱动oART可在前列腺癌放疗中改善每日靶区覆盖,尤其对淋巴结阳性患者PTV V95%提升更明显。
- 治疗时间因淋巴结受累情况而异,前列腺-only病例中位25分钟,淋巴结病例32分钟。
局限性
- 样本量较小(31例),未报告统计效能或置信区间。
- 靶区手动勾画可能引入操作者依赖性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Recent advances in Radiotherapy have led to the development of online adaptive RT (oART), a procedure addressing inter-fraction anatomical variations. Integrating artificial intelligence (AI) into the oART procedure speeds up the process and reduces user dependency. This study investigates the dosimetric advantage of implementing AI-driven oART in prostate cancer. METHODS: A total of 31 prostate cancer patients treated with oART on an AI-integrated Linac were analyzed. Patients were categorized by nodal involvement. For prostate-only cases, the Clinical Target Volume (CTV) included the prostate and seminal vesicles (CTV1), with a 5 mm margin (8 mm caudally) for Planning Target Volume (PTV), named PTV1. For nodal cases, pelvic lymph nodes were added (and categorized as CTV2) with a 5 mm isotropic margin (PTV2). Daily CBCTs were acquired, with OARs (rectum, bladder, bowels) automatically segmented by the AI system, while targets were manually delineated. Two plans were generated: a predicted one, calculating the original plan's fluence on daily anatomy, and an adapted one, with complete fluence re-optimization. Daily DVH indicators for PTV(V95%), CTV(D98%), bladder (V65Gy), bowel (V45Gy), and rectum (V50Gy) were compared between predicted and adapted plans using the Wilcoxon-Mann-Whitney test. Total session time, from CBCT acquisition to treatment completion, was also recorded. RESULTS: oART treatment improved prostate coverage in both patient groups (+10.4% and +11.8% in PTV V95% for patients with and without lymph nodes) and CTV D98% (+2.6% with lymph nodes, +2.9% without). Improvements for arm 2 were smaller (+3.1% in PTV2 V95%, +2.2% in CTV2 D98%). Statistical differences were insignificant in OAR DVH indicators (p > 0.1). Median treatment time was 25 min and 32 min for prostate-only and lymph node cases, respectively. CONCLUSION: This study demonstrates that oART in prostate cancer results in a significant improvement in target coverage with no significant difference in OARs.
引用
- Preziosi F, Boschetti A, Catucci F, et al. AI-driven online adaptive radiotherapy in prostate cancer treatment: considerations on activity time and dosimetric benefits. Radiat Oncol. 2025. PMID: 40713724. doi:10.1186/s13014-025-02697-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。